Phase 1 Trial of 61Cu-NODAGA-PSMA for Prostate Cancer
This study is testing a new way to image prostate cancer using a special tracer called 61Cu-NODAGA-PSMA. This tracer helps doctors see prostate cancer cells better on a PET/CT scan. The main goal is to check if 61Cu-NODAGA-PSMA is safe and doesn't cause too many side effects. Researchers will also look at how well it images prostate cancer compared to standard imaging. You might be able to join if you are a man, 18 or older, have prostate cancer confirmed by a biopsy, and have prostate cancer that shows up on a PSMA-targeted PET/CT scan. The study is currently enrolling a small number of participants.
- Study design
- This is a Phase 1 study, meaning it's an early-stage trial to check safety. It is not randomized and plans to enroll 6-10 participants.
- What's involved
- You would receive an intravenous (IV) injection of 61Cu-NODAGA-PSMA, followed by a PET/CT scan about an hour later. Side effects will be monitored for up to 24 hours after the injection.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for up to 24 hours after receiving the radiotracer.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Imaging Agent-Emergent Adverse Events [Safety and Tolerability]Up to 24 hours after administration of radiotracer
For the primary objective of safety, side effects will be monitored the day of and the day following radiotracer administration.